San Diego-based Illumina (NASDAQ: [[ticker:ILMN]]) CEO Jay Flatley told analysts and investors that some researchers “are beginning to wait a little while to do the next version of the genome-wide association study before the next-generation (equipment) ships.” The anticipated slowdown is expected to be temporary. Illumina makes sophisticated machines that enable scientists to do full genome sequencing by rapidly scanning genetic markers across complete sets of DNA.